Biomarkers · Inflammation
Myeloperoxidase (MPO)
Lower values go with lower risk of death. Not measured in our NHANES panel. The curve is drawn from the published study (source below).
MPO and risk of death
Published curve higher than the NHANES fitNHANES fit higher
Risk of death relative to the curve's reference value, drawn from the published study (source below).
Published risk of death1.97×highest MPO tertile (>=140.7 ug/L) vs lowest tertile (<=61.5 ug/L) (95% CI 1.02–3.80) · ilSIRENTE Study: all individuals aged 80+ living in a mountain community, Italy (frail octogenarians and nonagenarians)
What studies found when this marker was changed
They describe what happened in those study groups, not a recommendation. See all catalogued interventions.
| Type | Intervention | Reported effect | Evidence | Source |
|---|---|---|---|---|
| pharmacologic | Low-dose colchicine 0.5 mg once daily for 12 months in patients with acute coronary syndrome and lipid-rich plaque on OCT | Myeloperoxidase geometric mean ratio 0.8 with colchicine vs 1.0 with placebo at 12 months (difference 0.8, 95% CI 0.6 to 1.0; P=0.047) | RCT | Yu M, et al. Circulation. 2024. Effect of Colchicine on Coronary Plaque… |
Sources
- Risk curve: Giovannini S 2010 (PMID 20064836): all-cause HR 1.97 (1.02-3.8) highest MPO tertile (>=140.7 ug/L) vs lowest tertile (<=61.5 ug/L). Scaled to published population values.
- Giovannini S, Onder G, Leeuwenburgh C, Carter C, Marzetti E, Russo A, Capoluongo E, Pahor M, Bernabei R, Landi F. Myeloperoxidase levels and mortality in frail community-living elderly individuals. J Gerontol A Biol Sci Med Sci. 2010;65(4):369-376.
Map Myeloperoxidase (MPO) against another biomarker.
Related markers: Alpha-1-Antichymotrypsin (AACT) · Alpha-1-Antitrypsin (AAT) · Antinuclear Antibodies (ANA) · CD4:CD8 T-Cell Ratio · CD8+ T-Cell Count · Erythrocyte Sedimentation Rate (ESR) · Fibrinogen · Growth Differentiation Factor-15 (GDF-15)